Pain Management · NSAIDRegulatory Approvalregulatorymid-term

Aurobindo Pharma's Diclofenac Sodium ANDA076152 Receives AP Status

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma31 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/24/2026, 12:30:35 AM

Assessment confidence: 49% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval status for Aurobindo Pharma's Diclofenac Sodium could significantly impact the competitive dynamics within the pain management market. Companies with existing NSAID products should closely evaluate their market positioning and pricing strategies in light of this development. Regulatory context from FDA (FDA AP — DICLOFENAC SODIUM (SUPPL)) supports the near-term read. Assessment grounded in 9 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing NSAID products. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 3 regulatory and 4 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status may enhance Aurobindo's position in the competitive landscape of pain management therapies, particularly against other generic and branded NSAIDs.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DICLOFENAC SODIUM (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The approval status indicates a successful regulatory pathway for Aurobindo, which may prompt other companies to expedite their own applications or adjust their strategies accordingly.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Aurobindo's entry into the market with an approved generic could pressure pricing and market share for existing NSAID products, potentially affecting revenue streams for competitors.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for existing NSAID products.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the review process and potential launch timelines for Diclofenac Sodium.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DICLOFENAC SODIUM (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIVALPROEX SODIUM (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RISEDRONATE SODIUM (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DEXAMETHASONE SODIUM PHOSPHATE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAlow relevance
Regulatory pathway relevance (nda)
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pain Neuroscience Education for Chronic Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
FDA Approves ANDA for Tofacitinib Citrate by Sun Pharma
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, an
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Diclofenac Sodium

Commercial impact

medium

Aurobindo's entry into the market with an approved generic could pressure pricing and market share for existing NSAID products, potentially affecting revenue streams for competitors.

Regulatory impact

medium

The approval status indicates a successful regulatory pathway for Aurobindo, which may prompt other companies to expedite their own applications or adjust their strategies accordingly.

What to watch

Monitor for further updates on the review process and potential launch timelines for Diclofenac Sodium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.